We have demonstrated that SRC inhibitors can synergise with MEK inhibitors in CRC cell lines that depend on RAS‐MAPK signalling for survival and invasion, and inhibiting SRC may form part of wider combination regimens that will be most effective when tailored to the pathway activation status of specific patient tumours, and/or to mitigate against enhanced invasion caused by particular therapies such as those targeting MEK. The gene discussed is SRC; the disease is neoplasm.